Clinical Trial Update: SYN023 With Rabies Vaccine in Healthy Pediatric Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating SYN023 with a rabies vaccine for rabies post-exposure prophylaxis in healthy pediatric subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• Rabies vaccine (rabies vaccine)
• SYN023 (SYN023)

Snippet

Sponsor: Synermore Biologics (Suzhou) Co., Ltd. | Conditions: Rabies Post-exposure Prophylaxis | Phase 1 | Status: COMPLETED